Global Ventricular Assist Devices Market Research Report: By Product Type (Left
Ventricular Assist Device, Right Ventricular Assist Device, Biventricular Assist
Device), By Type of Flow (Continuous Flow, Pulsatile Flow), By Design
(Implantable Ventricular Assist Device, Transcutaneous Ventricular Assist Device)
and By Application (Destination Therapy, Bridging Therapy) – Forecast to 2027
According to MRFR analysis, the Global Ventricular Assist Devices Market is expected to
register a CAGR of 11.2% during the forecast period of 2020 to 2027 and accounted for
USD 1,726 Million in 2019.
A ventricular assist device (VAD) is a miniaturized mechanical pump used to support heart
function and maintain blood flow to vital organs in patients with weakened hearts. This
device can be used if one or both the heart's ventricles don't function properly. The growth
of the global ventricular assist device market can be attributed to factors such as the
increasing prevalence of cardiovascular disorders, rising cases of patients with heart failure,
shortage of heart donors, development of technologically advanced products, increasing
number of government initiatives to support medical device manufacturers, and a large
number of clinical trials to develop advanced VADs.
Get Sample Report at
However, risks associated with VAD implantation procedures, and unfavorable
reimbursement framework are likely to thwart the growth of the global ventricular assist
device market during the forecast period.
Some of the key players in the global ventricular assist devices market are Medtronic plc
(Ireland), Abbott (US), Berlin Heart GmbH (Germany), ReliantHeart Inc. (US), Abiomed Inc.
(US), Cardiac Assist Inc. (US), Cirtec (US), CorWave SA (France), and Fineheart (France)
The global ventricular assist devices market has been segmented based on product type,
type of flow, design, and application.